Project in line with forcasts

The research program is being managed according to roadmap. Each partner was able to initiate research as planned, and partnership between different research specialties have been initiated. Allocated budget and expenditures were in line with forecasts.

Two project meetings were held during the first year. Consortium agreement helped to frame the project from an administrative and legal perspective. Quality management: AXO Science is ISO 9001: 2008, ISO 13485: 2003 and NF EN ISO 13485: 2012 certified since December 2012. These certifications were maintained following March 10th 2015 audit conducted by notified body LNE / GMED. AXO Science quality manager ensures AXO Science management system applies to all project activities including HIFI Cap. Product specifications document was established and developed features were defined.

Research and development program will continue according to the original schedule.
A further meeting between the different partners will be held in 2015 Q4.

A new format for DNA-based applications

Financed by the Fonds Unique Interministériel and with a total budget of 1,95M€, the HIFI Cap research project brings together innovative disciplines such as nanotechnologies, high-throughput diagnostic analysis and multiplexed characterization of human biological samples.

The consortium constituted of AXO Science, the ICBMS (UMR5246) and Nano-H (nanotechnologies/nanomedicine) is to develop a new microcapsule test format, allowing both amplification and identification of genes in a single fully automated step with a scalable throughput. Innovation is to bring together, in a closed microcapsule, PCR reagents, the sample and the microarray, allowing the identification of amplified genes and a magnetic densitometric hybridization marker (high density optical nanoparticles).

This innovative approach will help future DNA-based diagnostic applications to be more time and cost efficient while reducing risk of contamination between samples. Above all, this new format will allow numerous DNA-based applications, for instance in the field of infectious diseases with gastroenteritis and respiratory infections associated pathogen panels.